anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Morphological changes in hip dysplasia The dysplastic hip joint has a complex morphology characterised by a wide shallow acetabular cavity with an excessively oblique articulating roof. The acetabular cover of the femoral head is globally deficient4;5 and the acetabular rim is hypertrophied possibly due to excessive pull from the often hypertrophic labrum. Anteversion is normal5-7, but occasionally the acetabulum is retroverted8;9. The weight-bearing area between the acetabular roof and head is reduced and the articular cartilage is significantly thicker than normal10. Hip dysplasia is often associated with increased anteversion of the femoral neck5;11 and with valgus neck-shaft angle that results in a reduced abductor lever arm12. However the deformities vary from individual to individual and retroversion of the femoral neck has also been reported in hip dysplasia12. Patients with hip dysplasia are prone to developing osteoarthritis of the hip at a young age 13;14. The reasons for this are not fully understood, but an explanation could be that the reduced contact area between acetabulum and the femoral head as well as a reduced abductor lever arm increase the load per contact-area in the hip joint4. The increased load is a strain on the articular cartilage and believed to result in degeneration of cartilage and the subchondral bone and eventually osteoarthritis14-17. The purpose of periacetabular osteotomy (PAO) is to increase acetabular cover of the femoral head and thereby distribute pressures better over the available cartilage surface.

PAO followed by rehabilitation At PAO, the pubic bone is osteotomized and under fluoroscopic control, the ischial osteotomies and the posterior iliac osteotomy are performed. The acetabular fragment is repositioned to optimise coverage of the femoral head. The repositioning is very challenging and clearly the most demanding aspect of the procedure18. Four weeks after discharge, the rehabilitation is initiated and carried out by two physiotherapists specialised in orthopaedics. The patients come to the hospital for physiotherapy twice a week and each exercise session is 1 hour with a 30-minute aerobic and strength program followed by a 30-minute program of mobility and gait training. Physiotherapy is ended 2-3 months after PAO when the physiotherapists assess that the patient has achieved predetermined functional goals e.g. walking at speed without crutches and ability to run. As a result of the patients' young age, they have had a high physical function and it is the aim, that they will regain this level of function after PAO. It is not yet examined whether PAO patients after surgery attain the functional capacity comparable to the age- and gender-matched population.
Benazepril hydrochloride and hydrochlorothiazide can cause symptomatic hypotension. Like other ACE inhibitors, benazepril has been only rarely associated with hypotension in uncomplicated hypertensive patients. Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. Volume and/or salt depletion should be corrected before initiating therapy with benazepril hydrochloride and hydrochlorothiazide.

Benazepril hydrochloride and hydrochlorothiazide should be used cautiously in patients receiving concomitant therapy with other antihypertensives. The thiazide component of benazepril hydrochloride and hydrochlorothiazide may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic-blocking drugs. The antihypertensive effects of the thiazide component may also be enhanced in the postsympathectomy patient.

In patients with congestive heart failure, with or without associated renal insufficiency, ACE inhibitor therapy may cause excessive hypotension, which may be associated with oliguria, azotemia, and (rarely) with acute renal failure and death. In such patients, benazepril hydrochloride and hydrochlorothiazide therapy should be started under close medical supervision; they should be followed closely for the first 2 weeks of treatment and whenever the dose of benazepril or diuretic is increased.

If hypotension occurs, the patient should be placed in a supine position, and, if necessary, treated with intravenous infusion of physiological saline. Benazepril hydrochloride and hydrochlorothiazide treatment usually can be continued following restoration of blood pressure and volume.
BACKGROUND: Outpatient psychotherapy is qualitatively and quantitatively an important treatment option for patients with psychological disorders. Additionally, there is the option of inpatient care, including psychosomatic rehabilitation units. There is a lack of data on the cooperation between the ambulatory and the inpatient sector, and on which patients in outpatient psychotherapy have already been in psychosoamtic rehabilitation or should be admitted.
METHOD: 131 psychotherapists were interview with regard to 322 cases they had recently seen with focus on the ongoing treatment, previous rehabilitation-treatments and current indications for rehabilitation programs.
RESULTS: Almost all patients were suffering from year long disorders. More than every second patient had problems at work. Together, these are core criteria for psychosomatic rehabilitation. 28% had already been in inpatient rehabilitation and another 28% were seen in need of inpatient rehabilitation. Comparison of patients who had been, were in need, or did not need such treatment showed that rehabilitation patients were older, had a lower education, were more severe ill, showed a more problematic course of treatment, had more problems with participation and needed more socio-medical support.
DISCUSSION: Results suggest that psychotherapists treat many patients, who fullfilled admission criteria for inpatient rehabilitation. They are important cooperation partners of rehabilitation units. Pension and health care insurance should support cooperation. Because of the great number of patients there is also the need to sharpen the criteria for inpatient treatment.
The DP included 25g of soy protein, 14g of dehydrated nopal,14g of oats, 4g of chia seeds, 4g of inulin, and 0.15g of flavoring. The DP was provided in a dehydrated form in a packet containing 30g each. The content of each packet was dissolved in 250ml of water.
The proposed project will fill a critical gap in the evidence base and answer the important question: can pivoting ARI CDS tools towards nurses overcome established implementation barriers to reducing antibiotic use? The proposal is highly innovative in three ways: It uses CDS tools to embed evidence-based risk stratification to enable nurse-led ARI management. It creates a nurse training program to support this nurse-led ARI treatment pathway. It will be evaluated and optimized using evidence-based implementation frameworks that will guide assessment of the fidelity, acceptability, adoption, cost, and sustainability of the tool. This will provide comprehensive implementation measures, formative and summative, and enable a rigorous understanding of barriers and facilitators to implementing nurse-led CDS tools for reducing antibiotic overprescribing. This study will provide much needed guidance on how to implement CDS-enabled, nurse-led ARI assessment and treatment to reduce antibiotic overprescribing.
Hidradenitis suppurativa (HS) is a chronic skin disease characterized by painful, recurrent abscesses, nodules, and scarring, primarily in skin folds. The exact causes of HS are multifactorial, involving genetic, hormonal, and environmental factors. It is associated with systemic diseases such as metabolic syndrome and inflammatory bowel disease. Genetic studies have identified mutations in the γ-secretase complex that affect Notch signaling pathways critical for skin cell regulation. Despite its high heritability, most reported HS cases do not follow a simple genetic pattern. In this article, we performed whole-exome sequencing (WES) on a cohort of 100 individuals with HS, and we provide a comprehensive review of the variants known to be described or associated with HS. 91 variants were associated with the γ-secretase complex, and 78 variants were associated with other genes involved in the Notch pathway, keratinization, or immune response. Through this new genetic analysis, we have added ten new variants to the existing catalogs. All variants are available in a .vcf file and are provided as a resource for future studies.
Childhood obesity is associated with comorbidities that affect almost all body systems, including, among others, the endocrine, gastrointestinal, pulmonary, cardiovascular and musculoskeletal systems, as well as medical and surgical procedures that may be required due to different clinical situations. The objective of this article is to describe the classic and emerging comorbidities associated with obesity and the complications of procedures that involve invasive manoeuvres. Although some of the problems associated with obesity during childhood are widely known, such as musculoskeletal and cutaneous disorders or apnoea-hypopnoea syndrome, others, such as changes in kidney function, non-alcoholic fatty liver and cardiometabolic risk, have received less attention due to their insidious development, as they may not manifest until adulthood. In contrast, there is another group of comorbidities that may have a greater impact due to their frequency and consequences, which are psychosocial problems. Finally, in the context of invasive medico-surgical interventions, obesity can complicate airway management. The recognition of these pathologies in association with childhood obesity is of vital importance not only in childhood but also due to their ramifications in adulthood.
BACKGROUND: There is interest in the public health impact of Long COVID, defined as symptoms that persist or begin after SARS-CoV-2 infection. We aimed to identify demographic and clinical risk factors associated with Long COVID over time in an Upper Middle-Income Country (UMIC) and potential biomarkers predictive of symptom trajectory.
METHODS: Prospective cohort study of adults with mild SARS-COV-2 during the Omicron period. We tracked symptom persistence and IgG antibody titers against the spike S1 subunit.
RESULTS: Of 383 participants, 276 had confirmed SARS-CoV-2 infection. Long COVID persisted for ≥ two months in 21 % and ≥ 12 months in 5 %. The most common symptoms were fatigue, upper respiratory symptoms, and myalgia/arthralgia: 15 % had fatigue for ≥ one month, 10 % for ≥ two months, and 5 % ≥ three months. Upper respiratory symptoms lasted ≥ one month in 17 %, ≥ two months in 7 %, and ≥ three months in 3 %. Fully 9 % reported myalgia/arthralgia lasting ≥ one month, 6 % ≥ two months, and 4 % ≥ three months. Risk factors for symptom persistence included female sex, not being fully vaccinated, and comorbidities. Participants experiencing persistent fatigue had lower anti-S1 IgG titers.
CONCLUSIONS: In this population, symptom persistence declined after the acute phase, but 5 % of participants did not fully recover. Even in a population that was almost fully vaccinated, women, individuals with comorbidities, and the few remaining people who were unvaccinated were at greater risk for Long COVID. Immunoglobulins may have utility as a biomarker of Long COVID fatigue in this population.
PIWI-interacting RNAs (piRNAs) are a typical class of small non-coding RNAs, which are essential for gene regulation, genome stability and so on. Accumulating studies have revealed that piRNAs have significant potential as biomarkers and therapeutic targets for a variety of diseases. However current computational methods face the challenge in effectively capturing piRNA-disease associations (PDAs) from limited data. In this study, we propose a novel method, MRDPDA, for predicting PDAs based on limited data from multiple sources. Specifically, MRDPDA integrates a deep factorization machine (deepFM) model with regularizations derived from multiple yet limited datasets, utilizing separate Laplacians instead of a simple average similarity network. Moreover, a unified objective function to combine embedding loss about similarities is proposed to ensure that the embedding is suitable for the prediction task. In addition, a balanced benchmark dataset based on piRPheno is constructed and a deep autoencoder is applied for creating reliable negative set from the unlabeled dataset. Compared with three latest methods, MRDPDA achieves the best performance on the pirpheno dataset in terms of the five-fold cross validation test and independent test set, and case studies further demonstrate the effectiveness of MRDPDA.
Raloxifene is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM). The biological actions of raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (agonism) and blockade of estrogenic pathways in others (antagonism). The agonistic or antagonistic action of raloxifene depends on the extent of recruitment of coactivators and corepressors to estrogen receptor (ER) target gene promoters.  
  
Raloxifene appears to act as an estrogen agonist in bone. It decreases bone resorption and bone turnover, increases bone mineral density (BMD) and decreases fracture incidence. Preclinical data demonstrate that raloxifene is an estrogen antagonist in uterine and breast tissues. These results are consistent with findings in clinical trials, which suggest that raloxifene hydrochloride lacks estrogen-like effects on the uterus and breast tissue.
A make-up composition for the skin, a process of preparation and a make-up application method are outlined. The invention relates in particular to a cosmetic composition comprising from 75 to 98% by weight of a powder or a mixture of powders, as well as at least one cosmetically acceptable lipophilic gel formed by a fatty phase comprising at least one oil, said lipophilic gel additionally comprising a block copolymer of at least one styrene polymer and at least one olefin polymer, the olefin being other than styrene, or a mixture of these block copolymers. Preferred co-polymers are diblock or triblock co-polymers including ethylene/propylene/styrene and butylene/ethylene/styrene copolymers. These polymers may be hydrogenated. Preferred oils include hydrogenated polyisobutene, jojoba oil or isononyl isononanoate. The fatty phase may also comprise waxes or pasty fatty substances. The powder may comprise fillers, pearlescent agents, colouring agents (including pigments) and other cosmetically acceptable additives such as sunscreens, preservatives, antioxidants and fragrances. The composition may form a blusher, eye shadow, foundation, make-up base, gloss or anhydrous lip product.
The generator has a voltage divider with a number of dividing elements serially connected to each other between two power sources of different voltage levels from each other, and dividing levels from each other, and dividing a potential difference between the two power sources into a plurality of levels of voltage. A switch has a number of switch devices serially connected to each other between the two power sources. The switch devices on the side of one of the two power sources are connected to the output terminal. Trigger turns on the switch devices sequentially from that on the side of the output terminal. Reverse flow preventive circuit prohibits a current flowing through that of the switch devices which is currently turned on from flowing through the voltage dividing elements corresp. to the switch devices which have been already turned on.
The effectiveness of PAXIL CR for the treatment of Premenstrual Dysphoric Disorder (PMDD) utilizing a continuous dosing regimen has been established in 2 placebo‑controlled trials in female patients ages 18 to 46 (Studies 8 and 9 [N=672]). Patients in these trials met DSM‑IV criteria for PMDD. Of 1,030 patients including Study 10, who were treated with daily doses of PAXIL CR 12.5 or 25 mg/day, or placebo continuously throughout the menstrual cycle for a period of 3 menstrual cycles, the mean duration of the PMDD symptoms was approximately 11 ± 7 years. Patients on systemic hormonal contraceptives were excluded from these trials. Therefore, the efficacy of PAXIL CR in combination with systemic (including oral) hormonal contraceptives for the continuous daily treatment of PMDD is unknown. 

The VAS score is a patient‑rated instrument that mirrors the diagnostic criteria of PMDD as identified in the DSM‑IV, and includes assessments for mood, physical symptoms, and other symptoms associated with PMDD. In Studies 8 and 9, 12.5 mg/day and 25 mg/day of PAXIL CR were statistically significantly more effective than placebo as measured by change from baseline to Month 3 on the luteal phase VAS score. 

In an additional study employing luteal phase dosing (Study 11), patients (N = 366) were treated for the 2 weeks prior to the onset of menses with 12.5 or 25 mg/day of PAXIL CR or placebo for a period of 3 months. In this trial,12.5 mg/day and 25 mg/day of PAXIL CR, as luteal phase dosing, was statistically significantly more effective than placebo as measured by change from baseline to luteal phase VAS score at Month 3.

There is insufficient information to determine the effect of race or age on outcome in Studies 8, 9, 10, and 11.
A phosphate compound with HDAC inhibitory activity, and its preparation method and application are provided. The invention belongs to the technical field of medicines, and provides a phosphoric acid compound shown in a formula (I), or a conformational isomer thereof, or an optical isomer thereof. Formula I: . Experiments prove that the phosphate compounds shown in the formula (I) can effectively inhibit the activity of histone deacetylase HDACs, have obvious inhibition effect on the proliferation activity of tumor cells, and have no toxicity on normal mammary epithelial cells MCF-10A. Therefore, the compound has great potential in preparing histone deacetylase inhibitors and applications, including antitumor activity. The patent mainly introduces the structure, the preparation method and the application of the compound in preparing anti-breast cancer drugs.
INTRODUCTION: The nature of the relationship between inflammation, cardiovascular (CV) risk factors and atherosclerosis in axial spondyloarthritis (axSpA) remains largely unknown and sex differences in this regard are yet to be assessed.
METHODS: Study including 611 men and 302 women from the Spanish multicentre AtheSpAin cohort to assess CV disease in axSpA. Data on CV disease risk factors were collected both at disease diagnosis and at enrolment, and data on disease activity, functional indices and carotid ultrasonography only at enrolment.
RESULTS: After a median disease duration of 9 years, patients of both sexes who at disease diagnosis had elevated acute phase reactants (APRs), more frequently had hypertension and obesity. The same occurred with dyslipidaemia in men and with diabetes mellitus in women. At enrolment, CV risk factors were independently associated with APR and with activity and functional indices, with various sex differences. C reactive protein (CRP) values were inversely associated with HDL-cholesterol in men (β coefficient: -1.2 (95% CI: -0.3 to -0.07) mg/dL, p=0.001), while erythrocyte sedimentation rate values were positively associated with triglycerides in women (β coefficient: 0.6 (95% CI: 0.04 to 1) mg/dL, p=0.035). Furthermore, only women showed an independent relationship between insulin resistance parameters and APR or disease activity. Both men and women with high-very high CV risk according to the Systematic Assessment of Coronary Risk Evaluation 2 and CRP levels higher than 3 mg/L at diagnosis of the disease presented carotid plaques significantly more frequently than those with normal CRP levels at disease diagnosis.
CONCLUSION: Inflammation is associated with atherosclerosis and CV disease in axSpA. A gender-driven effect is observed in this relationship.
Treatment with BENLYSTA in adult patients significantly reduced circulating CD19+, CD20+, naïve, and activated B cells, and the SLE B‑cell subset at Week 52. Reductions in naïve and the SLE B‑cell subset were observed as early as Week 8 and sustained to Week 52. Memory cells increased initially and slowly declined toward baseline levels by Week 52.

Treatment with BENLYSTA in adult patients led to reductions in IgG and anti-double-stranded DNA antibodies (anti-dsDNA) which were observed as early as Week 8 and sustained through Week 52. In patients with low complement levels at baseline, treatment led to increases in complement C3 and C4 as early as Week 12 and were sustained through Week 52.

The pharmacodynamic response observed in Black patients (Trial 4) was consistent with the previous studies.

In patients with active lupus nephritis (Trial 5), following treatment with BENLYSTA, there was a decrease in serum IgG as early as Week 4, and subsequently there was an increase in serum IgG levels which was associated with decreased proteinuria. Reductions in autoantibodies, increases in complement, and reductions in circulating total B cells and B‑cell subsets observed were consistent with the SLE studies.

In Trial 6 (pediatric dosing), the pharmacodynamic response was consistent with the adult data.

The clinical relevance of above mentioned pharmacodynamic biomarkers has not been established.
A method, apparatus and method of making acupoint patches is disclosed. The acupoint patch of the present invention uses natural herbs as raw materials. It is made by combining traditional Chinese acupuncture therapy and contemporary transdermal controlled release technologies. The acupoint patch of the present invention is made with natural herb extracts using contemporary transdermal absorption technologies based on the characteristics of different acupoints. They can stay on the skin for 6-8 hours, during which period natural herb essence enters blood circulation and performs a sustainable regulating function. This is a feature unrivaled by traditional acupuncture.
Prodn. of a protein (I) with antitumour activity comprises administering to a rabbit a cpd. able to stimulate the reticuloendothelial system and then injecting the endotoxin of a grain negative bacterium. The crude (I) soln. prod. is then purified by (1) adsorption onto a basic anion exchanger, (2) elution and (3) gel filtration of the eluate through a gel able to separate substances of mol. wt. 30000-70000. Gel filtration is pref. carried out using a pH 6-9 buffer and the crude (I) used in the first stage is a soln. in a similar buffer of salt concn. not over 0.2M. (I) itself is also claimed. (I) has mol. wt. 34000-44000; isoelectric point at pH 3.6-4.2 and mobility in electrophoresis on cellulose acetate at pH 8,6 is 0.0001-0.000001 sq.m. per volt-sec. (I) is effective against a wide range of cancer cells but is not cytotoxic towards normal cells. It is not species-specific and can be used in human or veterinary medicine.